X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (1) 1
aged (1) 1
aged, 80 and over (1) 1
aged; aged, 80 and over; androgen antagonists/adverse effects; androgen antagonists/therapeutic use; antibodies, monoclonal/adverse effects; antibodies, monoclonal/pharmacology; antibodies, monoclonal/therapeutic use; antibodies, monoclonal, humanized; bone density/drug effects; bone density conservation agents/adverse effects; bone density conservation agents/pharmacology; bone density conservation agents/therapeutic use; bone remodeling/drug effects; denosumab; double-blind method; fractures, bone/epidemiology; fractures, bone/prevention & control; gonadotropin-releasing hormone/agonists; humans; incidence; injections, subcutaneous; lumbar vertebrae/drug effects; lumbar vertebrae/injuries; lumbar vertebrae/physiology; male; middle aged; orchiectomy; osteoporosis/chemically induced; osteoporosis/drug therapy; prostatic neoplasms/drug therapy; prostatic neoplasms/physiopathology; prostatic neoplasms/surgery; rank ligand/adverse effects; rank ligand/pharmacology; rank ligand/therapeutic use; spinal fractures/epidemiology; spinal fractures/prevention & control (1) 1
alendronate (1) 1
androgen antagonists - adverse effects (1) 1
androgen antagonists - therapeutic use (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
article (1) 1
bone density (1) 1
bone density - drug effects (1) 1
bone density conservation agents - adverse effects (1) 1
bone density conservation agents - pharmacology (1) 1
bone density conservation agents - therapeutic use (1) 1
bone remodeling - drug effects (1) 1
bone-mineral density (1) 1
complications (1) 1
denosumab (1) 1
double-blind method (1) 1
fractures (1) 1
fractures, bone - epidemiology (1) 1
fractures, bone - prevention & control (1) 1
gonadotropin-releasing hormone - agonists (1) 1
humans (1) 1
incidence (1) 1
index medicus (1) 1
injections, subcutaneous (1) 1
lumbar vertebrae - drug effects (1) 1
lumbar vertebrae - injuries (1) 1
lumbar vertebrae - physiology (1) 1
male (1) 1
medicine, general & internal (1) 1
men (1) 1
middle aged (1) 1
older people (1) 1
orchiectomy (1) 1
osteoporosis (1) 1
osteoporosis - chemically induced (1) 1
osteoporosis - drug therapy (1) 1
placebo (1) 1
postmenopausal women (1) 1
prostate cancer (1) 1
prostatic neoplasms - drug therapy (1) 1
prostatic neoplasms - physiopathology (1) 1
prostatic neoplasms - surgery (1) 1
randomized controlled-trial (1) 1
rank ligand - adverse effects (1) 1
rank ligand - pharmacology (1) 1
rank ligand - therapeutic use (1) 1
risk (1) 1
spinal fractures - epidemiology (1) 1
spinal fractures - prevention & control (1) 1
zoledronic acid (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 745 - 755
Men receiving androgen-deprivation therapy for nonmetastatic prostate cancer are at high risk for bone loss and fractures. This placebo-controlled study... 
ZOLEDRONIC ACID | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | FRACTURES | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.